1. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
- Author
-
DeAngelo, Daniel J, Advani, Anjali S, Marks, David I, Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, Jabbour, Elias, Merchant, Akil, Wang, Tao, Vandendries, Erik, Neuhof, Alexander, Kantarjian, Hagop, and O’Brien, Susan
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Oncology and Carcinogenesis ,Clinical Trials and Supportive Activities ,Hematology ,Childhood Leukemia ,Transplantation ,Orphan Drug ,Rare Diseases ,Cancer ,Pediatric Research Initiative ,Clinical Research ,Pediatric ,Pediatric Cancer ,Good Health and Well Being ,Acute Disease ,Adult ,Antineoplastic Agents ,Immunological ,Bone Marrow ,Humans ,Inotuzumab Ozogamicin ,Kaplan-Meier Estimate ,Middle Aged ,Neoplasm Recurrence ,Local ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Prognosis ,Treatment Outcome ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology ,Oncology and carcinogenesis - Abstract
Adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) have a poor prognosis, especially if disease burden is high. This post hoc analysis of the phase 3 INO-VATE trial examined the efficacy and safety of inotuzumab ozogamicin (InO) vs. standard of care chemotherapy (SC) among R/R ALL patients with low, moderate, or high disease burden, respectively, defined as bone marrow blasts (BMB) 90% (n = 30 vs. 30). Patients in the InO vs. SC arm with low, moderate, and high BMB%, respectively, had improved rates of complete remission/complete remission with incomplete hematologic recovery (74% vs. 46% [p = 0.0022], 75 vs. 27% [p
- Published
- 2020